NextCure Inc
Company Profile
Business description
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer’s disease.
Contact
9000 Virginia Manor Road
Suite 200
BeltsvilleMD20705
USAT: +1 240 399-4900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
43
Stocks News & Analysis
stocks
Oracle shares are up 87% in 2025. Is it a buy?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,057.60 | 48.70 | -0.53% |
CAC 40 | 7,826.35 | 45.67 | -0.58% |
DAX 40 | 23,559.57 | 51.76 | -0.22% |
Dow JONES (US) | 46,292.78 | 88.76 | -0.19% |
FTSE 100 | 9,209.44 | 13.88 | -0.15% |
HKSE | 26,518.65 | 359.53 | 1.37% |
NASDAQ | 22,573.47 | 215.50 | -0.95% |
Nikkei 225 | 45,630.31 | 136.65 | 0.30% |
NZX 50 Index | 13,181.31 | 44.77 | 0.34% |
S&P 500 | 6,656.92 | 36.83 | -0.55% |
S&P/ASX 200 | 8,764.50 | 50.50 | -0.57% |
SSE Composite Index | 3,853.64 | 31.81 | 0.83% |